Rajesh Shrotriya
Director/Board Member at GT BIOPHARMA, INC.
Net worth: - $ as of 29/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Luigi Lenaz | M | 83 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA.
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 26 years |
Michael Breen | M | 61 | 3 years | |
Abraham Noah Oler | M | 48 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 14 years |
Bimal Shah | M | 48 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 14 years |
Manu Ohri | M | 68 | 2 years | |
Terrence Wright | M | 74 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Charles Casamento | M | 78 | 1 years | |
Jeffrey R. Latts | M | 76 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 17 years |
Keith M. McGahan | M | - | 8 years | |
Bruce Wendel | M | 70 | 4 years | |
James E. Shields | M | 72 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 14 years |
Michael A. Grabow | M | - | 11 years | |
Greg McKinley | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
John Midby | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Daniel Byron | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Jeffrey Shaw | M | 65 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Johnny Ribeiro | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Raj Chanderraj | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Bill Drobkin | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Greg Fullmer | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Jim Medick | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Daniel Giraldo | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Daniel Tuntland | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Jennie Dorsey | F | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
John Guedry | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Thomas Morton | M | 55 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
John F. O'Reilly | M | 78 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Roberto R. Denis | M | 74 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
David R. Belding | M | 78 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | 32 years |
Robert C. Melendres | M | 59 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Michael W. Yackira | M | 72 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Blake Sartini | M | 65 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
James Murren | M | 62 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Mark Frissora | M | 68 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Michael E. Schick | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 15 years |
Tony A. Marnell | M | 74 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Frank E. Martin | M | 77 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
William J. Paulos | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
William C. Wortman | M | - |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Brian Greenspun | M | 77 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Peter Thomas | M | 74 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Corey Sanders | M | 60 |
The UNLV Foundation
The UNLV Foundation Investment Trusts/Mutual FundsMiscellaneous The UNLV Foundation provides financial services. The non-profit company is based in Las Vegas, NV and has subsidiaries in United States. | - |
Jeffrey Miller | M | - | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Anthony Cataldo | M | 73 | 12 years | |
Thomas Riga | M | 48 | 10 years | |
Joseph W. Turgeon | M | 66 | 9 years | |
Samuel Gulko | M | 92 | 6 years | |
Paul Berns | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 years |
Kurt Gustafson | M | 56 | 9 years | |
Elly Ryu | F | 43 | 10 years | |
Gavin Choy | M | - | - | |
Brett Scott | M | 73 | - | |
Gregory Berk | M | 66 | 2 years | |
Raymond Cohen | M | 65 | 7 years | |
Dolatrai Vyas | M | 80 | 9 years | |
Gilles Gagnon | M | 70 | - | |
Anthony Maida | M | 59 | 16 years | |
Dilip J. Mehta | M | 91 | 7 years | |
George Ng | M | 49 | 3 years | |
Ronald Spair | M | 58 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 2 years |
Alan Urban | M | 55 | 1 years | |
Robert Fralin | M | - | - | |
Cecilia Gonzalo | F | 49 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 years |
David Stout | M | 70 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 years |
Krishan K. Arora | M | 83 | 3 years | |
Marc H. Graboyes | M | 54 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 years |
Shyam K. Kumaria | M | 74 | - | |
Anton G. Gueth | M | 67 | 1 years | |
Hari Babu Varshney | M | 79 |
Dr. Bhim Rao Ambedkar University
| 6 years |
David Clark | M | 56 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 years |
Charles N. Blitzer | M | 83 |
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | 7 years |
Michael Handelman | M | 65 | 1 years | |
Leonard M. Greenstein | M | 48 | 7 years | |
Ricardo J. Gonzalez | M | 53 | 6 years | |
Jonathan Leff | M | 55 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 7 years |
Guru Reddy | M | - | - | |
Amit Bhupendra Shah | M | 57 | 3 years | |
Jennifer Carver | F | 70 | 2 years | |
Antonis Koutsoukos | M | - |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 years |
Steven Fruchtman | M | 73 | 2 years | |
Hemant Kumar | M | - |
Dr. Bhim Rao Ambedkar University
| 4 years |
Vijay Prakash Agarwal | M | 80 |
Dr. Bhim Rao Ambedkar University
| 1 years |
Christopher Nardo | M | 59 | 5 years | |
Sushil Kanubhai Shah | M | 77 |
The Grant Government Medical College
| 3 years |
Thomas V. Girardi | M | 84 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 11 years |
Anil Kumar Bhattacharya | M | 90 |
Dr. Bhim Rao Ambedkar University
| 3 years |
Andrew Sandler | M | 58 | 2 years | |
George Uy | M | 67 | 4 years | |
Sanjeev Gurunath Redkar | M | 56 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 13 years |
Denise Landry | F | - |
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | 13 years |
Mitchell P. Cybulski | M | 77 | - | |
Michael A. Adam | M | 66 | 2 years | |
John McManus | M | 60 | 1 years | |
Walter J. Lack | M | 76 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 11 years |
Kenneth Joseph Keller | M | 61 | 2 years | |
Luke Seikkula | M | 60 | 3 years | |
Amar P. Singh | M | 65 | 1 years | |
Bruce K. Bennett | M | 73 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 4 years |
Audrey F. Jakubowski | M | 81 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 9 years |
Kathy Quandt | F | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 95 | 95.00% |
India | 5 | 5.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Rajesh Shrotriya
- Personal Network